Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Diabetic Macular Edema
Clinical trial register · United States · industry-sponsored

Diabetic Macular Edema Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9128 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 04 Nov 2026, 03:16 UTC
9128
Studies in scope
industry-sponsored, all four open statuses
4968
Recruiting now
open to new participants
2189
Lead sponsors
across recruiting studies
Top states
California 13 Florida 12 Arizona 8 Illinois 8 Maryland 7
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Diabetic Macular Edema trials in the USA

16 of 9128 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Boehringer Ingelheim
Phase 1/2
49
Arizona, California, Connecticut, Florida, New York, North Carolina, North Dakota, Ohio
2026-05-14
Recruiting
Genentech, Inc.
Phase 1
93
Arizona, California, Florida, Maryland, Pennsylvania, Tennessee, Texas, Virginia
2026-04-21
Active, closed
EyePoint Pharmaceuticals, Inc.
Phase 3
240
California, Colorado, Florida, Georgia, Hawaii, Illinois, Indiana, Louisiana
2026-02-16
Active, closed
EyePoint Pharmaceuticals, Inc.
Phase 3
240
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Kentucky
2026-02-09
Active, closed
Eclipse Life Sciences, Inc.
Phase 1/2
75
Florida
2024-08-19
Active, closed
Regeneron Pharmaceuticals
Phase 3
1,126
California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois, Maryland
2024-07-24
Recruiting
Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
NCT05802329Center Involved Diabetic Macular Edema, Diabetic Macular Edema
Ocugen
Phase 1
24
Florida, Pennsylvania, Texas, Wisconsin
2024-01-13
Active, closed
4D-150 in Patients With Diabetic Macular Edema
NCT05930561Diabetic Macular Edema, Diabetic Retinopathy
4D Molecular Therapeutics
Phase 2
72
Maryland, Oregon, Pennsylvania, Texas, Virginia
2023-08-09
Active, closed
AiViva BioPharma, Inc.
Phase 1
19
California, Oregon, Texas
2023-03-02
Active, closed
Genentech, Inc.
Phase 1
151
Arizona, Arkansas, California, Florida, Maryland, Michigan, Minnesota, Mississippi
2022-12-08
Active, closed
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
NCT05476926Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Branch Retinal Vein Occlusion
Hoffmann-La Roche
Observational
6,000
Arizona, California, Florida, Illinois, Kentucky, Maryland, Michigan, Pennsylvania
2022-11-21
Active, closed
Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME
NCT05387837Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
Ashvattha Therapeutics, Inc.
Phase 2
50
California, Illinois, Indiana, Maryland, Massachusetts, Missouri, New Jersey, Pennsylvania
2022-08-31
Active, closed
Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)
NCT05607810Diabetic Macular Edema, Diabetic Retinopathy
Adverum Biotechnologies, Inc.
Observational
22
California, Nevada, Pennsylvania, Texas
2022-08-10
Active, closed
Genentech, Inc.
Phase 4
218
Arizona, California, Colorado, District of Columbia, Florida, Illinois, Maryland, Michigan
2022-02-28
Active, closed
Alimera Sciences
Phase 4
300
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Louisiana
2020-08-31
Rows per page Showing 1–16 of 16
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 5 November 2026. https://priyalifescience.com/clinical-trials-usa/condition/diabetic-macular-edema

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,128 studies in total at the last sync on 04 Nov 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 16 of those studies listing the condition Diabetic Macular Edema.

How many Diabetic Macular Edema trials are recruiting in the US?

3 of the 16 studies on this page are recruiting new participants as of the 04 Nov 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 13 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Diabetic Macular Edema), 16 studies
PhaseStudiesRecruitingShare
Phase 14225%
Phase 34025%
Observational2012.5%
Phase 1/22112.5%
Phase 22012.5%
Phase 42012.5%

Most active sponsors

Lead sponsors with the most studies (Diabetic Macular Edema)
Lead sponsorStudiesRecruiting
Genentech, Inc.31
EyePoint Pharmaceuticals, Inc.20
Hoffmann-La Roche20
4D Molecular Therapeutics10
Adverum Biotechnologies, Inc.10
AiViva BioPharma, Inc.10
Alimera Sciences10
Ashvattha Therapeutics, Inc.10
Boehringer Ingelheim11
Eclipse Life Sciences, Inc.10

Top states

Top states (Diabetic Macular Edema), by number of studies with a site there
StateStudies
California13
Florida12
Arizona8
Illinois8
Maryland7
Colorado6
Pennsylvania6
Texas5
Connecticut4
Georgia4
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.